Thromboxane-A Synthase

Subscribe to Selected New Research on Thromboxane-A Synthase

326 relevant articles (26 outcomes, 40 trials/studies) found for this Bio-Agent

Description: An enzyme found predominantly in platelet microsomes. It catalyzes the conversion of PGG(2) and PGH(2) (prostaglandin endoperoxides) to thromboxane A2. EC 5.3.99.5.

Also Known As:

Thromboxane A Synthase; Thromboxane A2 Synthetase; A2 Synthetase, Thromboxane; Synthase, Thromboxane A; Synthase, Thromboxane-A; Synthetase, Thromboxane; Synthetase, Thromboxane A2; Thromboxane Synthetase; (5Z,13E)-(15S)-9alpha,11alpha-Epidioxy-15-hydroxyprosta-5,13-dienoate thromboxane-A(2)-isomerase

Relationship Network

Bio-Agent Context: Research Results

Enzymes and Coenzymes: 1

Enzymes: 24394

Isomerases: 18

Intramolecular Oxidoreductases

Thromboxane-A Synthase: 326

RS 86328

Experts

1.	Hirsch, Andrew M: 1 article (05/2002)
2.	Simonneau, Gerald: 1 article (05/2002)
3.	Riedel, Axel: 1 article (05/2002)
4.	Badesch, David B: 1 article (05/2002)
5.	Solèr, Markus: 1 article (05/2002)
6.	Naeije, Robert: 1 article (05/2002)
7.	Dias, Virgil C: 1 article (05/2002)
8.	Higenbottam, Timothy W: 1 article (05/2002)
9.	Seeger, Werner: 1 article (05/2002)
10.	Barst, Robyn J: 1 article (05/2002)

Related Diseases

1.	Ischemia 07/01/1996 - "Thromboxane synthetase inhibitor ameliorates delayed neuronal death in the CA1 subfield of the hippocampus after transient global ischemia in gerbils." 01/01/1986 - "This study was performed to examine potential protective effects of UK 38.485, an inhibitor of thromboxane synthetase, in canine myocardium stressed by transient ischemia" 01/01/1987 - "Protective effects of selective inhibitor of thromboxane synthetase (OKY-046) and thromboxane antagonist (ONO-3708) on ischemia-induced mitochondrial dysfunction in canine heart." 04/01/1988 - "Platelets are suggested to exacerbate ischemia-induced myocardial injury, which has led to the study of various antiplatelet therapies including thromboxane synthetase inhibitors (TXSI)" 02/01/1999 - "The anti-thromboxane A2 synthetase activity of myocardial tissue and its variation during ischemia and reperfusion in isolated rabbit heart." Order ALL the reference details at left...
2.	Myocardial Infarction 04/01/1989 - "This study was carried out to test this hypothesis with a new thromboxane synthetase inhibitor, and to extend the studies to alternative animal models of myocardial infarction" 10/01/1986 - "Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046)." 03/01/1985 - "U-63,557A, a new selective thromboxane synthetase inhibitor, was evaluated for its ability to prevent the extension of myocardial infarct size" 03/01/1985 - "Protective action of a thromboxane synthetase inhibitor in preventing extension of infarct size in acute myocardial infarction." 02/01/1991 - "Inhibition of thromboxane A2 synthetase failed to limit myocardial infarct size in a rabbit ischemia-reperfusion model." Order ALL the reference details at left...
3.	Septic Shock (Toxic Shock Syndrome) 06/01/1997 - "Protective effects of a thromboxane synthetase inhibitor and continuous arteriovenous hemofiltration in rat endotoxic shock." 06/01/1980 - "Protective effects of thromboxane synthetase inhibitors in rats in endotoxic shock." 05/01/1986 - "Improvement in organ blood flow by inhibition of thromboxane synthetase during experimental endotoxic shock in the rat." 01/01/1983 - "Thromboxane synthetase inhibitors in septic shock." 04/01/1983 - "Effects of a pyridine derivative thromboxane synthetase inhibitor and its inactive isomer in endotoxic shock in the rat." Order ALL the reference details at left...
4.	Shock 06/01/1983 - "Protective effects of thromboxane A2 synthetase inhibitors on endotoxin shock." 09/01/1987 - "In some shock models, however, results with thromboxane synthetase inhibitors have been conflicting" 07/01/1991 - "These data show that a selective thromboxane synthetase inhibitor (OKY-046) does not improve the blood rheology during endotoxin shock, although it seems to prevent the acidosis in some extent." 01/01/1988 - "Both 150 and 300 mg/kg doses of picotamide significantly (P less than 0.05) improved survival in endotoxin shock at 48 hr. These studies demonstrate that picotamide is a selective thromboxane synthetase inhibitor, and that it may be useful during disease states characterized by increased TxA2 synthesis." 02/15/1990 - "Protective effect of Y-20811, a long-lasting thromboxane synthetase inhibitor, on endotoxin shock in rabbits." Order ALL the reference details at left...
5.	Glomerulonephritis 03/01/1992 - "Thromboxane synthetase inhibitors have been used successfully to treat experimentally induced glomerulonephritis in several species and this treatment appears to hold promise for naturally occurring glomerulonephritis in dogs." 10/01/1986 - "Effect of a thromboxane synthetase inhibitor on eicosanoid synthesis and glomerular injury during acute unilateral glomerulonephritis in the rat." 05/01/1992 - "Effects of a thromboxane synthetase inhibitor on established immune complex glomerulonephritis in dogs." 03/01/1991 - "Effects of thromboxane synthetase inhibition on immune complex glomerulonephritis." 10/01/1988 - "Effects of a specific thromboxane synthetase inhibitor on development of experimental Dirofilaria immitis immune complex glomerulonephritis in the dog." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Thromboxane A2 (A2, Thromboxane)
2.	Epoprostenol (Prostacyclin)
3.	dazmegrel
4.	dazoxiben
5.	ozagrel
6.	Thromboxane Receptors (Thromboxane Receptor)
7.	Aspirin (Acetylsalicylic Acid)
8.	Lipoxygenase (Lipoxygenase-1)
9.	Prostaglandin H2 Thromboxane A2 Receptors
10.	picotamide

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Chemoprevention
3.	Liver Transplantation
4.	Homologous Transplantation (Allograft)
5.	Endarterectomy (Thromboendarterectomy)

Best Treatments:
Research Summary Report
on Ischemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 2711 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>